190 related articles for article (PubMed ID: 34778040)
21. Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study.
Emral R; Haymana C; Demirci I; Tasci I; Sahin M; Cakal E; Ata N; Unluturk U; Demir T; Ertugrul D; Sahin I; Atmaca A; Celik O; Caglayan M; Arga KY; Dagdelen S; Salman S; Satman I; Sonmez A
Diabetes Ther; 2021 Nov; 12(11):2857-2870. PubMed ID: 34398433
[TBL] [Abstract][Full Text] [Related]
22. Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.
Ha KH; Kim DJ; Choi YJ
J Diabetes Investig; 2022 Jun; 13(6):986-996. PubMed ID: 35132815
[TBL] [Abstract][Full Text] [Related]
23. Sodium-glucose co-transporter 2 inhibitors and the risk of fractures: A propensity score-matched cohort study.
Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1629-1639. PubMed ID: 31646732
[TBL] [Abstract][Full Text] [Related]
24. Sodium-glucose cotransporter 2 inhibitors and the risk of venous thromboembolism: A population-based cohort study.
Aloe S; Filliter C; Salmasi S; Igweokpala S; Yu OHY; Tagalakis V; Filion KB
Br J Clin Pharmacol; 2023 Sep; 89(9):2902-2914. PubMed ID: 37183930
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
[TBL] [Abstract][Full Text] [Related]
26. Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Front Pharmacol; 2021; 12():689885. PubMed ID: 34650428
[TBL] [Abstract][Full Text] [Related]
27. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
28. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
[No Abstract] [Full Text] [Related]
29. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
[TBL] [Abstract][Full Text] [Related]
30. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
Zhuo M; Hawley CE; Paik JM; Bessette LG; Wexler DJ; Kim DH; Tong AY; Kim SC; Patorno E
JAMA Netw Open; 2021 Oct; 4(10):e2130762. PubMed ID: 34705014
[TBL] [Abstract][Full Text] [Related]
31. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Suissa S
Diabetes Care; 2018 Jan; 41(1):6-10. PubMed ID: 29263192
[TBL] [Abstract][Full Text] [Related]
32. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study.
Chen YC; Chen TH; Sun CC; Chen JY; Chang SS; Yeung L; Tsai YW
Acta Diabetol; 2020 Oct; 57(10):1181-1192. PubMed ID: 32318876
[TBL] [Abstract][Full Text] [Related]
33. Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Br J Clin Pharmacol; 2018 Sep; 84(9):2029-2039. PubMed ID: 29766544
[TBL] [Abstract][Full Text] [Related]
34. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
Komamine M; Kajiyama K; Ishiguro C; Uyama Y
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
[TBL] [Abstract][Full Text] [Related]
36. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.
Mui JV; Zhou J; Lee S; Leung KSK; Lee TTL; Chou OHI; Tsang SL; Wai AKC; Liu T; Wong WT; Chang C; Tse G; Zhang Q
Front Cardiovasc Med; 2021; 8():747620. PubMed ID: 34746262
[No Abstract] [Full Text] [Related]
37. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea.
Yang H; Choi E; Park E; Na E; Chung SY; Kim B; Han SY
Pharmacol Res Perspect; 2022 Feb; 10(1):e00910. PubMed ID: 35005849
[TBL] [Abstract][Full Text] [Related]
38. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
[TBL] [Abstract][Full Text] [Related]
39. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
[TBL] [Abstract][Full Text] [Related]
40. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study.
Kim YG; Jeon JY; Kim HJ; Kim DJ; Lee KW; Moon SY; Han SJ
J Clin Med; 2018 Dec; 8(1):. PubMed ID: 30597861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
